Rusolo F, Capone F, Pasquale R, Angiolillo A, Colonna G, Castello G, Costantini M, Costantini S
For increased patient safety in APAP consumption, the FDA has worked to mitigate APAP hepatotoxicity by legislating regulations to limit prescription combination drug products to have no more than 325 mg of APAP per dosage unit and have urged healthcare providers to cease prescribing combination drug products with more than 325 mg of APAP per tablet
In the renal impairment study, this was in part owing to disruption by the COVID-19 pandemic, with temporary closure of the two study centres
Articles featured on Noah are for informational purposes only and should not be constituted as medical advice, diagnosis or treatment
No published pharmacokinetic studies directly measure this interaction, making it impossible to quantify safe spacing or dosing adjustments
Medical guidance the way it should be